HER2 Positive Metastatic Breast Cancer Clinical Trial
Official title:
Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer : a Single-arm, Open-label, Ahead Study
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study of pyrotinib plus capecitabine as the Therapy of brain metastases from HER2-positive metastatic breast cancer.
Brain metastases occur in 30-50% of patients with metastatic HER2-positive breast cancer. In the case of solitary brain metastases, surgery or stereotactic radiosurgery are the preferred therapeutic approaches.Chemotherapy is used after further progression of disease but it has limited effectiveness. In HER2-positive tumours, trastuzumab therapy has been postulated to be associated with an increased risk of development of brain metastases.Thus new therapeutic options are urgently needed to improve patients'outcome. Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. We designed the study to explore the possibility of pyrotinib plus capecitabine for brain metastases from HER2-positive metastatic breast cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04829604 -
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
|
Phase 2 | |
| Active, not recruiting |
NCT03080805 -
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)
|
Phase 3 | |
| Active, not recruiting |
NCT02422199 -
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
|
Phase 1/Phase 2 | |
| Terminated |
NCT01495884 -
The Myocet/Lapatinib Study. ICORG 10-03, V5
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02973737 -
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT04398108 -
A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
|
Phase 1 | |
| Active, not recruiting |
NCT04681287 -
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
|
Phase 2 |